Ketamine blocked NMDA-dependent bursting activity in the LHb and reversed depression-like symptoms (Yang et al., 2018), implicating the NMDA receptor and Kir4.1 in the LHb as potential targets for treatment of depression. Here, KCNJ10 is linked to depressive symptom measurement.